Search

Your search keyword '"Asao, Tetsuhiko"' showing total 234 results
Start Over Author "Asao, Tetsuhiko"
234 results on '"Asao, Tetsuhiko"'

1. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

Author

Nishioka, Naoya, Imai, Hisao, Endo, Masahiro, Notsu, Akifumi, Doshita, Kosei, Igawa, Satoshi, Yokouchi, Hiroshi, Ninomiya, Takashi, Tokito, Takaaki, Soda, Sayo, Fujiwara, Takasato, Asao, Tetsuhiko, Nakamichi, Shinji, Kawamura, Takahisa, Inomata, Minehiko, Nakashima, Kazuhisa, Ito, Kentaro, Goto, Yasuhiro, Umeda, Yukihiro, Hirai, Soichi, Ushio, Ryota, Yokoo, Keiki, Takeda, Takayuki, Fukui, Tomoya, Ishihara, Masashi, Osaki, Takashi, Kubo, Sousuke, Fujiwara, Takumi, Yamamoto, Chie, Tsuda, Takeshi, Tamura, Nobumasa, Hosokawa, Shinobu, Chihara, Yusuke, Ikeda, Satoshi, Furuya, Naoki, Nakahara, Yoshiro, Miura, Satoru, and Okamoto, Hiroaki

Published
2024
Full Text
View/download PDF

2. Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancer

Author

Matsumoto, Naohisa, Tajima, Ken, Takahashi, Fumiyuki, Mitsuishi, Yoichiro, Wirawan, Aditya, Hidayat, Moulid, Winardi, Wira, Wibowo, Adityo, Hayakawa, Daisuke, Izumi, Kenta, Kanamori, Koichiro, Miyashita, Yosuke, Handa, Takafumi, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Shimada, Naoko, Takamochi, Kazuya, Hayashi, Takuo, Suzuki, Kenji, and Takahashi, Kazuhisa

Published
2024
Full Text
View/download PDF

3. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)

Author

Asao, Tetsuhiko, Shukuya, Takehito, Uemura, Kohei, Kitadai, Rui, Yamamoto, Gaku, Mouri, Atsuto, Tamaoka, Meiyo, Imai, Ryosuke, Tsukita, Yoko, Isobe, Kazutoshi, Watanabe, Satoshi, Kamimura, Mitsuhiro, Morita, Ryo, Kudo, Keita, Inomata, Minehiko, Tateishi, Kazunari, Kakinuma, Kazutaka, Yoshioka, Hiroshige, Namba, Yukiko, Sumiyoshi, Issei, Nakagawa, Taku, Watanabe, Kana, Kobayashi, Kunihiko, and Takahashi, Kazuhisa

Published
2024
Full Text
View/download PDF

4. Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer

Author

Fujimoto, Daichi, Miura, Satoru, Tomii, Keisuke, Sumikawa, Hiromitsu, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Yokoyama, Toshihide, Kijima, Takashi, Asao, Tetsuhiko, Tamiya, Motohiro, Nakamura, Atsushi, Yoshioka, Hiroshige, Tokito, Takaaki, Murakami, Shuji, Tamiya, Akihiro, Yokouchi, Hiroshi, Watanabe, Satoshi, Yamaguchi, Ou, Morinaga, Ryotaro, Jodai, Takayuki, Ito, Kentaro, Shiraishi, Yoshimasa, Kogure, Yoshihito, Shibaki, Ryota, and Yamamoto, Nobuyuki

Published
2023
Full Text
View/download PDF

13. Multimodal fully automated predictive model for therapeutic efficacy of first-line cancer immunotherapy based on clinical information and imaging modalities including brain MRI and chest CT images in advanced non-small cell lung cancer.

Author

Miyawaki, Taichi, primary, Shukuya, Takehito, additional, Suzuki, Kazuhiro, additional, Xu, Shiting, additional, Nakamura, Yusuke, additional, Katayama, Isana, additional, Shirai, Yukina, additional, Matsuda, Hironari, additional, Fujioka, Masahiro, additional, Miyashita, Yosuke, additional, Koinuma, Yoshika, additional, Asao, Tetsuhiko, additional, Kanemaru, Ryota, additional, Shimamura, Shoko, additional, Mitsuishi, Yoichiro, additional, Shibayama, Rina, additional, Tajima, Ken, additional, Shimada, Naoko, additional, Otsuka, Yujiro, additional, and Takahashi, Kazuhisa, additional

Published
2024
Full Text
View/download PDF

14. SCLC-J1, a novel small cell lung cancer cell line

Author

Ohara, Kazuo, Kinoshita, Shintaro, Ando, Jun, Azusawa, Yoko, Ishii, Midori, Harada, Sakiko, Mitsuishi, Yoichiro, Asao, Tetsuhiko, Tajima, Ken, Yamamoto, Taketsugu, Takahashi, Fumiyuki, Komatsu, Norio, Takahashi, Kazuhisa, and Ando, Miki

Published
2021
Full Text
View/download PDF

15. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study

Author

Fujimoto, Daichi, Miura, Satoru, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Yokoyama, Toshihide, Yokoi, Takashi, Asao, Tetsuhiko, Tamiya, Motohiro, Nakamura, Atsushi, Yoshioka, Hiroshige, Haratani, Koji, Teraoka, Shunsuke, Tokito, Takaaki, Murakami, Shuji, Tamiya, Akihiro, Itoh, Shoichi, Yokouchi, Hiroshi, Watanabe, Satoshi, Yamaguchi, Ou, Tomii, Keisuke, and Yamamoto, Nobuyuki

Published
2021
Full Text
View/download PDF

16. Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy.

Author

Masui, Yoshihiro, Shukuya, Takehito, Kataoka, Shunichi, Shiozaki, Hitomi, Kurokawa, Kana, Nakamura, Ikuko, Miyawaki, Taichi, Koinuma, Yoshika, Asao, Tetsuhiko, Kanemaru, Ryota, Shimamura, Shoko Sonobe, Mimori, Tomoyasu, Mitsuishi, Yoichiro, Tajima, Ken, Shimada, Naoko, and Takahashi, Kazuhisa

Subjects
COMBINATION drug therapy, CANCER relapse, PROTEIN-tyrosine kinase inhibitors, IMMUNE checkpoint inhibitors, LUNG tumors, STATISTICS, LUNG cancer, COMPARATIVE studies, PATIENTS' attitudes, SECONDARY primary cancer
Abstract

Objectives: This study aimed to investigate the characteristics of patients with recurrent or advanced non‐small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors (TKIs) or immune‐checkpoint inhibitors (ICIs) who developed secondary malignancies, as well as evaluate the impact of these secondary malignancies on the course of lung cancer. Materials and Methods: This study included 112 patients with postoperative recurrent or advanced NSCLC, who received TKIs, ICIs, or immune combination therapy as the primary treatment modality between April 1, 2013, and March 31, 2020, and achieved long‐term survival (≥2 years). Secondary malignancies were defined as newly diagnosed cancers in other organs occurring after NSCLC treatment initiation. Results: Among the 112 patients, 10 (8.9%) developed 12 carcinomas, including third primary malignancies. Univariate analysis, considering secondary malignancies as the outcome, revealed a non‐significant trend towards a higher incidence of secondary malignancies in smokers compared to non‐smokers. Conclusion: This study found that 8.9% of patients with advanced NSCLC who received TKIs, ICIs, or immune combination therapy and survived ≥2 years developed secondary malignancies. This underscores the importance of early diagnosis and treatment, even during lung cancer treatment, to identify suspicious lesions in other organs either via imaging or physical examinations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older.

Author

Yagishita, Shigehiro, Yamanaka, Yuta, Kurata, Takayasu, Watanabe, Kageaki, Hosomi, Yukio, Horinouchi, Hidehito, Ohe, Yuichiro, Nakahara, Yoshiro, Naoki, Katsuhiko, Asao, Tetsuhiko, Takahashi, Kazuhisa, Saeki, Sho, Sakagami, Takuro, Nakashima, Kazuhisa, Tsubata, Yukari, Fujita, Yu, Wakui, Hiroshi, Furuta, Megumi, Konishi, Jun Sakakibara, and Ohuchi, Mayu

Subjects
OLDER patients, GERIATRIC assessment, LUNG cancer, OVERALL survival, PEMBROLIZUMAB
Abstract

Pembrolizumab is a major treatment for recurrent or advanced non‐small‐cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited. This open‐label, multicenter, observational study evaluated real‐world data on the safety, efficacy, and PK of pembrolizumab in older patients with NSCLC. In 99 patients aged ≥75 years, PK was determined by liquid chromatography–mass spectrometry on pretreatment samples. Performance status (PS), geriatric assessment (GA), overall response rate (ORR), progression‐free survival (PFS), and overall survival (OS) were evaluated. The median age was 78 (75–87) years. PS was 2–3 in 14 patients. The median ORR, PFS, and OS were 47.5%, 8.0, and 20.5 months, respectively. Although PK and ORR were not significantly associated, patients with the lowest Cycle 1‐trough quartile (Q1) experienced poorer PFS (Q1 vs. Q2–4; 3.4 vs. 11.8 months, P = 0.006) and OS (Q1 vs. Q2–4; 9.9 vs. 21.7 months, P = 0.005) than in other quartiles overall, and even in the PD‐L1 ≥50% subset (PFS, Q1 vs. Q2–4; 4.1 vs. 14.7 months, P = 0.005; OS, Q1 vs. Q2–4; 9.4 vs. 22.1 months, P = 0.010). The Q1 subgroup was characterized by poor PS and lower albumin, and more frequent "weight loss ≥ 10%" on the GA. Pembrolizumab therapy had similar PK and efficaciousness in older as well as younger patients. In patients with PS ≥2, low albumin, and vulnerable GA, early increases in PK levels are less likely, potentially diminishing efficacy even when PD‐L1 ≥50%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study.

Author

Torasawa, Masahiro, Shukuya, Takehito, Uemura, Kohei, Hayashi, Takuo, Ueno, Toshihide, Kohsaka, Shinji, Masui, Yoshihiro, Shirai, Yukina, Okura, Makiko, Asao, Tetsuhiko, Mitsuishi, Yoichiro, Shimada, Naoko, Takahashi, Fumiyuki, Takamochi, Kazuya, Suzuki, Kenji, Takahashi, Kazuhisa, and Seyama, Kuniaki

Subjects
TUMOR suppressor genes, LUNG cancer, TUBEROUS sclerosis, LUNG diseases, CANCER patients, VON Hippel-Lindau disease
Abstract

Background and Objective: Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease associated with the functional tumour suppressor genes TSC1 and TSC2 and causes structural destruction in the lungs, which could potentially increase the risk of lung cancer. However, this relationship remains unclear because of the rarity of the disease. Methods: We investigated the relative risk of developing lung cancer among patients diagnosed with LAM between 2001 and 2022 at a single high‐volume centre in Japan, using data from the Japanese Cancer Registry as the reference population. Next‐generation sequencing (NGS) was performed in cases where tumour samples were available. Results: Among 642 patients diagnosed with LAM (sporadic LAM, n = 557; tuberous sclerosis complex‐LAM, n = 80; unclassified, n = 5), 13 (2.2%) were diagnosed with lung cancer during a median follow‐up period of 5.13 years. All patients were female, 61.5% were never smokers, and the median age at lung cancer diagnosis was 53 years. Eight patients developed lung cancer after LAM diagnosis. The estimated incidence of lung cancer was 301.4 cases per 100,000 person‐years, and the standardized incidence ratio was 13.6 (95% confidence interval, 6.2–21.0; p = 0.0008). Actionable genetic alterations were identified in 38.5% of the patients (EGFR: 3, ALK: 1 and ERBB2: 1). No findings suggested loss of TSC gene function in the two patients analysed by NGS. Conclusion: Our study revealed that patients diagnosed with LAM had a significantly increased risk of lung cancer. Further research is warranted to clarify the carcinogenesis of lung cancer in patients with LAM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

Author

Nakamichi, Shinji, primary, Kubota, Kaoru, primary, Misumi, Toshihiro, primary, Kondo, Tetsuro, primary, Murakami, Shuji, primary, Shiraishi, Yoshimasa, primary, Imai, Hisao, primary, Harada, Daijiro, primary, Isobe, Kazutoshi, primary, Itani, Hidetoshi, primary, Takata, Saori, primary, Wakui, Hiroshi, primary, Misumi, Yuki, primary, Ikeda, Satoshi, primary, Asao, Tetsuhiko, primary, Furuya, Naoki, primary, Hosokawa, Shinobu, primary, Kobayashi, Yumiko, primary, Takiguchi, Yuichi, primary, and Okamoto, Hiroaki, primary

Published
2024
Full Text
View/download PDF

20. Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

Author

Nakamichi, Shinji, primary, Kubota, Kaoru, primary, Misumi, Toshihiro, primary, Kondo, Tetsuro, primary, Murakami, Shuji, primary, Shiraishi, Yoshimasa, primary, Imai, Hisao, primary, Harada, Daijiro, primary, Isobe, Kazutoshi, primary, Itani, Hidetoshi, primary, Takata, Saori, primary, Wakui, Hiroshi, primary, Misumi, Yuki, primary, Ikeda, Satoshi, primary, Asao, Tetsuhiko, primary, Furuya, Naoki, primary, Hosokawa, Shinobu, primary, Kobayashi, Yumiko, primary, Takiguchi, Yuichi, primary, and Okamoto, Hiroaki, primary

Published
2024
Full Text
View/download PDF

21. Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

Author

Nakamichi, Shinji, primary, Kubota, Kaoru, primary, Misumi, Toshihiro, primary, Kondo, Tetsuro, primary, Murakami, Shuji, primary, Shiraishi, Yoshimasa, primary, Imai, Hisao, primary, Harada, Daijiro, primary, Isobe, Kazutoshi, primary, Itani, Hidetoshi, primary, Takata, Saori, primary, Wakui, Hiroshi, primary, Misumi, Yuki, primary, Ikeda, Satoshi, primary, Asao, Tetsuhiko, primary, Furuya, Naoki, primary, Hosokawa, Shinobu, primary, Kobayashi, Yumiko, primary, Takiguchi, Yuichi, primary, and Okamoto, Hiroaki, primary

Published
2024
Full Text
View/download PDF

22. Usefulness of Computed Tomography for Evaluating the Effects of Bronchial Thermoplasty in Japanese Patients with Severe Asthma

Author

Abe,Sumiko, Yasuda,Mina, Tobino,Kazunori, Harada,Sonoko, Sasano,Hitoshi, Tanabe,Yuki, Sandhu,Yuuki, Takeshige,Tomohito, Matsuno,Kei, Asao,Tetsuhiko, Sueyasu,Takuto, Nishizawa,Saori, Yoshimine,Kohei, Ko,Yuki, Yoshimatsu,Yuki, Tsuruno,Kosuke, Ide,Hiromi, Takagi,Haruhi, Ito,Jun, Nagaoka,Tetsutaro, Harada,Norihiro, Takahashi,Kazuhisa, Abe,Sumiko, Yasuda,Mina, Tobino,Kazunori, Harada,Sonoko, Sasano,Hitoshi, Tanabe,Yuki, Sandhu,Yuuki, Takeshige,Tomohito, Matsuno,Kei, Asao,Tetsuhiko, Sueyasu,Takuto, Nishizawa,Saori, Yoshimine,Kohei, Ko,Yuki, Yoshimatsu,Yuki, Tsuruno,Kosuke, Ide,Hiromi, Takagi,Haruhi, Ito,Jun, Nagaoka,Tetsutaro, Harada,Norihiro, and Takahashi,Kazuhisa

Abstract

Sumiko Abe,1 Mina Yasuda,1,2 Kazunori Tobino,1,2 Sonoko Harada,1,3 Hitoshi Sasano,1 Yuki Tanabe,1 Yuuki Sandhu,1 Tomohito Takeshige,1 Kei Matsuno,1 Tetsuhiko Asao,1 Takuto Sueyasu,2 Saori Nishizawa,2 Kohei Yoshimine,2 Yuki Ko,2 Yuki Yoshimatsu,2 Kosuke Tsuruno,2 Hiromi Ide,2 Haruhi Takagi,1 Jun Ito,1 Tetsutaro Nagaoka,1 Norihiro Harada,1,3,4 Kazuhisa Takahashi1,4 1Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan; 2Department of Respiratory Medicine, Iizuka Hospital, Fukuoka, Japan; 3Atopy (Allergy) Research Center, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan; 4Research Institute for Diseases of Old Age, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, JapanCorrespondence: Norihiro Harada, Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan, Tel +81-3-5802-1063, Fax +81-3-5802-1617, Email nor@juntendo.ac.jpBackground: Bronchial thermoplasty (BT) improves clinical outcomes and quality of life for patients with severe asthma and has shown sustained reductions in airway narrowing and air trapping in previous CT studies. However, there is a lack of a comprehensive analysis, including CT evaluation, of clinical outcomes in Japanese patients who have undergone BT for severe asthma. This study aimed to evaluate the impact of BT in Japanese asthma patients, with a focus on the CT metric “WA at Pi10” to assess airway disease.Methods: Twelve patients with severe persistent asthma who underwent BT were assessed using ACQ6, AQLQ, pulmonary function tests, FeNO measurement, blood sampling, and chest CT before BT and one year after the third procedure for the upper lobes.Results: The median age of the patient was 62.0 years, 7/12 (58.3%) were male, 4/12 (33.3%) used regular oral corticosteroids, and 8/12 (66.7%) received biologics.

Published
2024

23. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)

Author

Nakamichi, Shinji, primary, Kubota, Kaoru, additional, Misumi, Toshihiro, additional, Kondo, Tetsuro, additional, Murakami, Shuji, additional, Shiraishi, Yoshimasa, additional, Imai, Hisao, additional, Harada, Daijiro, additional, Isobe, Kazutoshi, additional, Itani, Hidetoshi, additional, Takata, Saori, additional, Wakui, Hiroshi, additional, Misumi, Yuki, additional, Ikeda, Satoshi, additional, Asao, Tetsuhiko, additional, Furuya, Naoki, additional, Hosokawa, Shinobu, additional, Kobayashi, Yumiko, additional, Takiguchi, Yuichi, additional, and Okamoto, Hiroaki, additional

Published
2024
Full Text
View/download PDF

26. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)

Author

Asao, Tetsuhiko, primary, Shukuya, Takehito, additional, Mimori, Tomoyasu, additional, Goto, Yasushi, additional, Tanaka, Hiroshi, additional, Takayama, Koichi, additional, Tsubata, Yukari, additional, Tachihara, Motoko, additional, Suzuki, Takuji, additional, Kaira, Kyoichi, additional, Ko, Ryo, additional, Zenke, Yoshitaka, additional, Akamatsu, Hiroaki, additional, Tanizaki, Junko, additional, Ikeda, Satoshi, additional, Sugawara, Shunichi, additional, Mizutani, Hideaki, additional, Mori, Keita, additional, and Takahashi, Kazuhisa, additional

Published
2023
Full Text
View/download PDF

27. MO2-4 Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years

Author

Saeki, Sho, primary, Yamanaka, Yuta, additional, Kurata, Takayasu, additional, Watanabe, Kageaki, additional, Hosomi, Yukio, additional, Horinouchi, Hidehito, additional, Ohe, Yuichiro, additional, Nakahara, Yoshiro, additional, Asao, Tetsuhiko, additional, Tsubata, Yukari, additional, Fujita, Yu, additional, Konishi, Jun Sakakibara, additional, Mizugaki, Hidenori, additional, Ohuchi, Mayu, additional, Yagishita, Shigehiro, additional, and Hamada, Akinobu, additional

Published
2023
Full Text
View/download PDF

29. Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy

Author

Torasawa, Masahiro, primary, Horinouchi, Hidehito, additional, Nomura, Shogo, additional, Igawa, Satoshi, additional, Asai, Maiko, additional, Ishii, Hidenobu, additional, Wakui, Hiroshi, additional, Ushio, Ryota, additional, Asao, Tetsuhiko, additional, Namba, Yukiko, additional, Koyama, Ryo, additional, Hayakawa, Daisuke, additional, Katayama, Isana, additional, Matsuda, Hironari, additional, Sasaki, Shinichi, additional, Takahashi, Kazuhisa, additional, Hosomi, Yukio, additional, Naoki, Katsuhiko, additional, and Ohe, Yuichiro, additional

Published
2023
Full Text
View/download PDF

34. Usefulness of Computed Tomography for Evaluating the Effects of Bronchial Thermoplasty in Japanese Patients with Severe Asthma.

Author

Abe, Sumiko, Yasuda, Mina, Tobino, Kazunori, Harada, Sonoko, Sasano, Hitoshi, Tanabe, Yuki, Sandhu, Yuuki, Takeshige, Tomohito, Matsuno, Kei, Asao, Tetsuhiko, Sueyasu, Takuto, Nishizawa, Saori, Yoshimine, Kohei, Ko, Yuki, Yoshimatsu, Yuki, Tsuruno, Kosuke, Ide, Hiromi, Takagi, Haruhi, Ito, Jun, and Nagaoka, Tetsutaro

Subjects
JAPANESE people, ASTHMATICS, BLOOD sampling, COMPUTED tomography, PULMONARY function tests, VOCAL cord dysfunction, WHEEZE
Abstract

Background: Bronchial thermoplasty (BT) improves clinical outcomes and quality of life for patients with severe asthma and has shown sustained reductions in airway narrowing and air trapping in previous CT studies. However, there is a lack of a comprehensive analysis, including CT evaluation, of clinical outcomes in Japanese patients who have undergone BT for severe asthma. This study aimed to evaluate the impact of BT in Japanese asthma patients, with a focus on the CT metric "WA at Pi10" to assess airway disease. Methods: Twelve patients with severe persistent asthma who underwent BT were assessed using ACQ6, AQLQ, pulmonary function tests, FeNO measurement, blood sampling, and chest CT before BT and one year after the third procedure for the upper lobes. Results: The median age of the patient was 62.0 years, 7/12 (58.3%) were male, 4/12 (33.3%) used regular oral corticosteroids, and 8/12 (66.7%) received biologics. Median FEV1% was 73.6%, and median peripheral eosinophil count was 163.8/μL. After one year of BT, ACQ6 scores improved from 2.4 to 0.8 points (p = 0.007), and AQLQ scores improved from 4.3 to 5.8 points (p < 0.001). Significant improvements were also observed in asthma exacerbations, unscheduled visits due to exacerbations, FeNO, and √WA at Pi10 (p < 0.05). The baseline mucus score on the CT findings was negatively correlated with FEV1 (r = − 0.688, p = 0.013) and with the maximum mid-expiratory flow rate (r = − 0.631, p = 0.028), and positively correlated with the peripheral blood eosinophil count (r = − 0.719, p = 0.008). Changes in √WA at Pi10 after one year were positively correlated with changes in the mucus score (r = 0.742, p = 0.007). Conclusion: This study has limitations, including its single-arm observational design and the small sample size. However, BT led to a symptomatic improvement in patients with severe asthma. The validated "√WA at Pi10" metric on CT effectively evaluated the therapeutic response in Japanese asthma patients after BT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Abstract 2797: Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years

Author

Nakahara, Yoshiro, primary, Watanabe, Kageaki, additional, Hosomi, Yukio, additional, Yamanaka, Yuta, additional, Kurata, Takayasu, additional, Horinouchi, Hidehito, additional, Ohe, Yuichiro, additional, Asao, Tetsuhiko, additional, Saeki, Sho, additional, Tsubata, Yukari, additional, Fujita, Yu, additional, Konishi, Jun Sakakibara, additional, Mizugaki, Hidenori, additional, Ohuchi, Mayu, additional, Yagishita, Shigehiro, additional, and Hamada, Akinobu, additional

Published
2023
Full Text
View/download PDF

39. Data from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1

Author

Wirawan, Aditya, primary, Tajima, Ken, primary, Takahashi, Fumiyuki, primary, Mitsuishi, Yoichiro, primary, Winardi, Wira, primary, Hidayat, Moulid, primary, Hayakawa, Daisuke, primary, Matsumoto, Naohisa, primary, Izumi, Kenta, primary, Asao, Tetsuhiko, primary, Ko, Ryo, primary, Shimada, Naoko, primary, Takamochi, Kazuya, primary, Suzuki, Kenji, primary, Abe, Masaaki, primary, Hino, Okio, primary, Sekido, Yoshitaka, primary, and Takahashi, Kazuhisa, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure S2 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1

Author

Wirawan, Aditya, primary, Tajima, Ken, primary, Takahashi, Fumiyuki, primary, Mitsuishi, Yoichiro, primary, Winardi, Wira, primary, Hidayat, Moulid, primary, Hayakawa, Daisuke, primary, Matsumoto, Naohisa, primary, Izumi, Kenta, primary, Asao, Tetsuhiko, primary, Ko, Ryo, primary, Shimada, Naoko, primary, Takamochi, Kazuya, primary, Suzuki, Kenji, primary, Abe, Masaaki, primary, Hino, Okio, primary, Sekido, Yoshitaka, primary, and Takahashi, Kazuhisa, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legends from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1

Author

Wirawan, Aditya, primary, Tajima, Ken, primary, Takahashi, Fumiyuki, primary, Mitsuishi, Yoichiro, primary, Winardi, Wira, primary, Hidayat, Moulid, primary, Hayakawa, Daisuke, primary, Matsumoto, Naohisa, primary, Izumi, Kenta, primary, Asao, Tetsuhiko, primary, Ko, Ryo, primary, Shimada, Naoko, primary, Takamochi, Kazuya, primary, Suzuki, Kenji, primary, Abe, Masaaki, primary, Hino, Okio, primary, Sekido, Yoshitaka, primary, and Takahashi, Kazuhisa, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table S2 from A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1

Author

Wirawan, Aditya, primary, Tajima, Ken, primary, Takahashi, Fumiyuki, primary, Mitsuishi, Yoichiro, primary, Winardi, Wira, primary, Hidayat, Moulid, primary, Hayakawa, Daisuke, primary, Matsumoto, Naohisa, primary, Izumi, Kenta, primary, Asao, Tetsuhiko, primary, Ko, Ryo, primary, Shimada, Naoko, primary, Takamochi, Kazuya, primary, Suzuki, Kenji, primary, Abe, Masaaki, primary, Hino, Okio, primary, Sekido, Yoshitaka, primary, and Takahashi, Kazuhisa, primary

Published
2023
Full Text
View/download PDF

43. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma

Author

Kanamori, Koichiro, primary, Suina, Kentaro, additional, Shukuya, Takehito, additional, Takahashi, Fumiyuki, additional, Hayashi, Takuo, additional, Hara, Kieko, additional, Saito, Tsuyoshi, additional, Mitsuishi, Yoichiro, additional, Shimamura, Shoko Sonobe, additional, Winardi, Wira, additional, Tajima, Ken, additional, Ko, Ryo, additional, Mimori, Tomoyasu, additional, Asao, Tetsuhiko, additional, Itoh, Masayoshi, additional, Kawaji, Hideya, additional, Suehara, Yoshiyuki, additional, Takamochi, Kazuya, additional, Suzuki, Kenji, additional, and Takahashi, Kazuhisa, additional

Published
2023
Full Text
View/download PDF

44. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines

Author

Xu, Shiting, primary, Miura, Keita, additional, Shukuya, Takehito, additional, Harada, Sonoko, additional, Fujioka, Masahiro, additional, Winardi, Wira, additional, Shimamura, Shoko, additional, Kurokawa, Kana, additional, Sumiyoshi, Issei, additional, Miyawaki, Taichi, additional, Asao, Tetsuhiko, additional, Mitsuishi, Yoichiro, additional, Tajima, Ken, additional, Takahashi, Fumiyuki, additional, Hayashi, Takuo, additional, Harada, Norihiro, additional, and Takahashi, Kazuhisa, additional

Published
2023
Full Text
View/download PDF

46. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer

Author

Kurokawa, Kana, primary, Mitsuishi, Yoichiro, additional, Shimada, Naoko, additional, Ito, Naoaki, additional, Ogiwara, Misa, additional, Miura, Keita, additional, Asao, Tetsuhiko, additional, Ko, Ryo, additional, Shukuya, Takehito, additional, Shibayama, Rina, additional, Goto, Hiromasa, additional, and Takahashi, Kazuhisa, additional

Published
2022
Full Text
View/download PDF

48. MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study

Author

Kitadai, Rui, primary, Asao, Tetsuhiko, additional, Shukuya, Takehito, additional, Yamamoto, Gaku, additional, Mouri, Atsuto, additional, Imai, Ryosuke, additional, Tsukita, Yoko, additional, Isobe, Kazutoshi, additional, Watanabe, Satoshi, additional, Kamimura, Mitsuhiro, additional, Morita, Ryo, additional, Kudo, Keita, additional, Inomata, Minehiko, additional, Tateishi, Kazunari, additional, Kakinuma, Kazutaka, additional, Yoshioka, Hiroshige, additional, Namba, Yukiko, additional, Nakagawa, Taku, additional, Kobayashi, Kunihiko, additional, and Takahashi, Kazuhisa, additional

Published
2022
Full Text
View/download PDF

49. A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).

Author

Nakamichi, Shinji, primary, Kubota, Kaoru, additional, Misumi, Toshihiro, additional, Murakami, Shuji, additional, Kondo, Tetsuro, additional, Okamoto, Isamu, additional, Minato, Koichi, additional, Harada, Daijiro, additional, Isobe, Kazutoshi, additional, Itani, Hidetoshi, additional, Takata, Saori, additional, Wakui, Hiroshi, additional, Misumi, Yuki, additional, Ikeda, Satoshi, additional, Asao, Tetsuhiko, additional, Inoue, Takeo, additional, Hosokawa, Shinobu, additional, Kobayashi, Yumiko, additional, Takiguchi, Yuichi, additional, and Okamoto, Hiroaki, additional

Published
2022
Full Text
View/download PDF

50. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study

Author

Kurokawa, Kana, primary, Mitsuishi, Yoichiro, additional, Shimada, Naoko, additional, Kawakami, Yuta, additional, Miura, Keita, additional, Miyawaki, Taichi, additional, Asao, Tetsuhiko, additional, Ko, Ryo, additional, Shukuya, Takehito, additional, Shibayama, Rina, additional, Nojiri, Shuko, additional, and Takahashi, Kazuhisa, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results